Skip to main content

Table 1 Altered m6A modification in cancer therapeutic resistance

From: Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance

Therapeutic resistance

Mechanisms

Cancer types

M6A regulators

Roles

Functions

Ref.

Chemoresistance

Drug transport

CRC

IGF2BP3↑

ABCB1↑

Doxorubicin resistance

[60]

HCC/breast cancer

METTL3↑

ERRγ↑ → ABCB1↑

Doxorubicin resistance

[61]

breast cancer

YTHDF2↓

ATF3↑ → ABCB1↑

Tamoxifen resistance

[62]

Autophagy

GC

FTO↑

mTORC1 signal pathway↓

5-Fu/cisplatin/paclitaxel resistance

[63]

Seminoma

METTL3↑

ATG5↑

Cisplatin resistance

[64]

DNA damage repair

CSCC

FTO↑

β-catenin↑ → ECCR1↑

Cisplatin resistance and radioresistance

[13]

breast cancer

YTHDC1↑

BRCA1/RAD51↑

Adriamycin resistance

[65]

seminoma

METTL3/IGF2BP1↑

TFAP2C↑ → WEE1/BRCA1 ↑

Cisplatin resistance

[66]

EMT and CSCs

CC

METTL3/IGF2BP1↑

CBX8↑ → LGR5↑

Oxaliplatin resistance

[67]

CRC

METTL3↑

Sec62↑ → Wnt/β-catenin signaling↑

5-Fu/oxaliplatin resistance

[68]

Glycolysis

BC

ALKBH5↓

CK2α↑

Cisplatin resistance

[69]

GBM

FTO↑

PDK1↑

Temozolomide resistance

[70]

Radioresistance

DNA damage repair

LUAD

IGF2BP2/3↑

VANGL1↑ → BRAF/TP53BP1/RAD51 pathway↑

Radioresistance

[71]

EMT and CSCs

ESCC

METTL14↓

miR-99a-5p↓ → TRIB2↑

Radioresistance

[72]

Targeted therapy resistance

Drug transport

NSCLC

FTO↑

ABCC10↑

Gefitinib resistance

[12]

HCC

METTL14↓

HNF3γ↓ → OATP1B1/3↓

Sorafenib resistance

[73]

Apoptosis

leukemia

FTO↑

BCL-2↑

TKIs resistance

[14]

Immunotherapy resistance

TME

–

METTL3↓

M1/M2-like TAM/Treg infiltration↑

Anti-PD-1 therapy resistance

[74]

melanoma

ALKBH5↑

Tregs/MDSCs accumulation↑

Anti-PD-1 therapy resistance

[75]

ICC

ALKBH5↓

PD-L1 ↓

Anti-PD-1/PD-L1 therapy resistance

[76]

CRC and melanoma

METTL3/14↑

CD8+ T cells/CXCL9/CXCL10 ↓

Anti-PD-1 therapy resistance

[77]